Your browser doesn't support javascript.
loading
The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma.
Pangarsa, Eko A; Naibaho, Ridho M; Yunarvika, Vina; Setiawan, Budi; Santosa, Damai; Suharti, Catharina.
  • Pangarsa EA; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
  • Naibaho RM; Trainee in Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
  • Yunarvika V; Department of Internal Medicine, Parikesit Hospital, Mulawarman School of Medicine, Samarinda, East Kalimantan, Indonesia.
  • Setiawan B; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
  • Santosa D; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
  • Suharti C; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
Case Rep Hematol ; 2021: 9632427, 2021.
Article en En | MEDLINE | ID: mdl-34777885
ABSTRACT
Up to 20-40% of patients with Hodgkin's lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin's lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Año: 2021 Tipo del documento: Article